Pearls and pitfalls in human pharmacological models of migraine: 30 Years' experience

Cephalalgia

Volumn 33, Issue 8, 2013, Pages 540-553

  Ashina, Messoud ^a   Hansen, Jakob Møller ^a   Olesen, Jes ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

drug targets; human models of migraine; Migraine; migraine provocation

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; DIPYRIDAMOLE; GLYCERYL TRINITRATE; HISTAMINE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PROPRANOLOL; PROSTAGLANDIN; SILDENAFIL; SUMATRIPTAN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; DISEASE MODEL; ENZYME INHIBITION; GENETIC SUSCEPTIBILITY; HEMIPLEGIC MIGRAINE; HUMAN; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NEUROIMAGING; PROPHYLAXIS; PROVOCATION TEST; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH; TREATMENT PLANNING; VASODILATATION;

DRUG TARGETS; HUMAN MODELS OF MIGRAINE; MIGRAINE; MIGRAINE PROVOCATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION; HISTAMINE; HUMAN EXPERIMENTATION; HUMANS; MIGRAINE DISORDERS; NITROGLYCERIN; PHOSPHODIESTERASE INHIBITORS; VASODILATOR AGENTS;

EID: 84877995374     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102412475234     Document Type: Article

References (128)

1. Hering C. Glonoine, a new medicine for headache etc. Am J Homeopathy 1849: 3.
2. Tfelt-Hansen PC, Tfelt-Hansen J. Nitroglycerin headache and nitroglycerin-induced primary headaches from 1846 and onwards: A historical overview and an update. Headache. 2009 ; 49: 445-456
3. Iversen HK, Olesen J, Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain. 1989 ; 38: 17-24
4. Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity: A possible molecular mechanism of migraine pain. Neuroreport. 1993 ; 4: 1027-1030
5. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004 ; 24: 9-160
6. Thomsen LL, Kruuse C, Iversen HK, et al. A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol. 1994 ; 1: 73-80
7. Sances G, Tassorelli C, Pucci E, et al. Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches. Cephalalgia. 2004 ; 24: 110-119
8. Afridi SK, Matharu MS, Lee L, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain. 2005 ; 128: 932-939
9. Bahra A, Matharu MS, Buchel C, et al. Brainstem activation specific to migraine headache. Lancet. 2001 ; 357: 1016-1017
10. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995 ; 1: 658-660
11. Afridi SK, Giffin NJ, Kaube H, et al. A positron emission tomographic study in spontaneous migraine. Arch Neurol. 2005 ; 62: 1270-1275
12. Afridi SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain. 2004 ; 110: 675-680
13. Sprenger T, Maniyar FH, Monteith TS, et al. Midbrain activation in the premonitory phase of migraine: A H2O-positron emission tomography study. In: American Headache Society 54th Annual Scientific Meeting, Los Angeles, CA, USA, 2012.
14. Headache 2012; 863-864.
15. Giffin NJ, Ruggiero L, Lipton RB, et al. Premonitory symptoms in migraine: An electronic diary study. Neurology. 2003 ; 60: 935-940
16. Nichols FT 3rd, Mawad M, Mohr JP, et al. Focal headache during balloon inflation in the internal carotid and middle cerebral arteries. Stroke. 1990 ; 21: 555-559
17. Thomsen LL, Iversen HK, Brinck TA, et al. Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers. Cephalalgia. 1993 ; 13: 395-399
18. Christiansen I, Iversen HK, Olesen J, et al. Nitric oxide-induced headache may arise from extracerebral arteries as judged from tolerance to isosorbide-5-mononitrate. J Headache Pain. 2008 ; 9: 215-220
19. Tegeler CH, Davidai G, Gengo FM, et al. Middle cerebral artery velocity correlates with nitroglycerin-induced headache onset. J Neuroimaging. 1996 ; 6: 81-86
20. Iversen HK, Holm S, Friberg L, et al. Intracranial hemodynamics during intravenous infusion of glyceryl trinitrate. J Headache Pain. 2008 ; 9: 177-180
21. Ashina M, Tfelt-Hansen P, Dalgaard P, et al. Lack of correlation between vasodilatation and pharmacologically induced immediate headache in healthy subjects. Cephalalgia. 2011 ; 31: 683-690
22. Hansen JM, Pedersen D, Larsen VA, et al. Magnetic resonance angiography shows dilatation of the middle cerebral artery after infusion of glyceryl trinitrate in healthy volunteers. Cephalalgia. 2007 ; 27: 118-127
23. Lassen LH, Ashina M, Christiansen I, et al. Nitric oxide synthase inhibition in migraine. Lancet. 1997 ; 349: 401-402
24. Tvedskov JF, Thomsen LL, Iversen HK, et al. The prophylactic effect of valproate on glyceryltrinitrate induced migraine. Cephalalgia. 2004 ; 24: 576-585
25. Friedman DI, De ver Dye T. Migraine and the environment. Headache. 2009 ; 49: 941-952
26. Hauge A, Kirchmann M, Olesen J. Trigger factors in migraine with aura. Cephalalgia. 2010 ; 30: 346-353
27. Schoonman GG, van der Grond J, Kortmann C, et al. Migraine headache is not associated with cerebral or meningeal vasodilatation - a 3T magnetic resonance angiography study. Brain. 2008 ; 131: 2192-2200
28. Thomsen LL, Iversen HK, Olesen J. Cerebral blood flow velocities are reduced during attacks of unilateral migraine without aura. Cephalalgia. 1995 ; 15: 109-116
29. Friberg L, Olesen J, Iversen HK, et al. Migraine pain associated with middle cerebral artery dilatation: Reversal by sumatriptan. Lancet. 1991 ; 338: 13-17
30. Asghar MS, Hansen AE, Amin FM, et al. Evidence for a vascular factor in migraine. Ann Neurol. 2011 ; 69: 635-645
31. Van der Schueren BJ, Lunnon MW, Laurijssens BE, et al. Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine?. J Clin Pharmacol. 2009 ; 49: 281-290
32. Hoivik HO, Laurijssens BE, Harnisch LO, et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia. 2010 ; 30: 1458-1467
33. Dieterle A, Fischer MJ, Link AS, et al. Increase in CGRP- and nNOS-immunoreactive neurons in the rat trigeminal ganglion after infusion of an NO donor. Cephalalgia. 2011 ; 31: 31-42
34. Annedi SC, Maddaford SP, Ramnauth J, et al. 3,5-Disubstituted indole derivatives as selective human neuronal nitric oxide synthase (nNOS) inhibitors. Bioorg Med Chem Lett. 2012 ; 22: 1980-1984
35. Fullerton T, Komorowski-Swiatek D, Forrest A, et al. The pharmacodynamics of sumatriptan in nitroglycerin-induced headache. J Clin Pharmacol. 1999 ; 39: 17-29
36. Iversen HK, Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia. 1996 ; 16: 412-418
37. Schmetterer L, Wolzt M, Krejcy K, et al. Cerebral and ocular hemodynamic effects of sumatriptan in the nitroglycerin headache model. Clin Pharmacol Ther. 1996 ; 60: 199-205
38. Tvedskov JF, Iversen HK, Olesen J, et al. Nitroglycerin provocation in normal subjects is not a useful human migraine model?. Cephalalgia. 2010 ; 30: 928-932
39. Tvedskov JF, Thomsen LL, Iversen HK, et al. The effect of propranolol on glyceryltrinitrate-induced headache and arterial response. Cephalalgia. 2004 ; 24: 1076-1087
40. Van der Schueren BJ, Blanchard R, Murphy MG, et al. The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men. Br J Clin Pharmacol. 2011 ; 71: 708-717
41. Tvedskov JF, Tfelt-Hansen P, Petersen KA, et al. CGRP receptor antagonist olcegepant (BIBN4096BS) does not prevent glyceryl trinitrate-induced migraine. Cephalalgia. 2010 ; 30: 1346-1353
42. Ashina M Human models - screening models. In: Ramadan N, Olesen J (eds) Innovative drug development for headache disorders. Oxford, UK: Oxford University Press, 2008.
43. Olesen J, Thomsen LL, Lassen LH, et al. The nitric oxide hypothesis of migraine and other vascular headaches. Cephalalgia. 1995 ; 15: 94-100
44. Pickering GW, Hess W. Headache produced by histamine and its mechanism. Br J Med. 1932 ; 2: 1097-1098
45. Clark D, Hough H, Wolff HG. Experimental studies on headache: Observations on headache produced by histamine. Arch NeuroPsych. 1936 ; 35: 1054-1069
46. Northfield DWC. Some observations on headache. Brain. 1938 ; 61: 133-162
47. Sicuteri F, Ricci M, Monfardini R, et al. Experimental headache with endogeneous histamine; first results obtained by 48/80, a histamine-liberator drug, in the cephalic and peripheral circulatory systems of man. Acta Allergol. 1957 ; 11: 188-192
48. Krabbe AA, Olesen J. Headache provocation by continuous intravenous infusion of histamine. Clinical results and receptor mechanisms. Pain. 1980 ; 8: 253-259
49. Lassen LH, Thomsen LL, Olesen J. Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine. Neuroreport. 1995 ; 6: 1475-1479
50. Lassen LH, Christiansen I, Iversen HK, et al. The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs. Cephalalgia. 2003 ; 23: 877-886
51. Levy D, Burstein R, Kainz V, et al. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain. 2007 ; 130: 166-176
52. Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 2: Neuroleptics, antihistamines, and others. Headache. 2012 ; 52: 292-306
53. Tek D, Mellon M. The effectiveness of nalbuphine and hydroxyzine for the emergency treatment of severe headache. Ann Emerg Med. 1987 ; 16: 308-313
54. Nanda RN, Arthur GP, Johnson RH, et al. Cimetidine in the prophylaxis of migraine. Acta Neurol Scand. 1980 ; 62: 90-95
55. Edvinsson L, Ekman R, Jansen I, et al. Peptide-containing nerve fibers in human cerebral arteries: Immunocytochemistry, radioimmunoassay, and in vitro pharmacology. Ann Neurol. 1987 ; 21: 431-437
56. Jansen I, Uddman R, Hocherman M, et al. Localization and effects of neuropeptide Y, vasoactive intestinal polypeptide, substance P, and calcitonin gene-related peptide in human temporal arteries. Ann Neurol. 1986 ; 20: 496-501
57. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988 ; 23: 193-196
58. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990 ; 28: 183-187
59. Ashina M, Bendtsen L, Jensen R, et al. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain. 2000 ; 86: 133-138
60. Tvedskov JF, Lipka K, Ashina M, et al. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol. 2005 ; 58: 561-568
61. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002 ; 22: 54-61
62. Hansen JM, Hauge AW, Olesen J, et al. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010 ; 30: 1179-1186
63. Lassen LH, Jacobsen VB, Haderslev PA, et al. Involvement of calcitonin gene-related peptide in migraine: Regional cerebral blood flow and blood flow velocity in migraine patients. J Headache Pain. 2008 ; 9: 151-157
64. Petersen KA, Lassen LH, Birk S, et al. BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther. 2005 ; 77: 202-213
65. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004 ; 350: 1104-1110
66. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008 ; 70: 1304-1312
67. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008 ; 372: 2115-2123
68. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011 ; 31: 712-722
69. Asghar MS, Hansen AE, Kapijimpanga T, et al. Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology. 2010 ; 75: 1520-1526
70. Iversen HK, Olesen J. Nitroglycerin-induced headache is not dependent on histamine release: Support for a direct nociceptive action of nitric oxide. Cephalalgia. 1994 ; 14: 437-442
71. Kruuse C, Thomsen LL, Jacobsen TB, et al. The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. J Cereb Blood Flow Metab. 2002 ; 22: 1124-1131
72. Kruuse C, Thomsen LL, Birk S, et al. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain. 2003 ; 126: 241-247
73. Kruuse C, Hansen AE, Larsson HB, et al. Cerebral haemodynamic response or excitability is not affected by sildenafil. J Cereb Blood Flow Metab. 2009 ; 29: 830-839
74. Kruuse C, Lassen LH, Iversen HK, et al. Dipyridamole may induce migraine in patients with migraine without aura. Cephalalgia. 2006 ; 26: 925-933
75. Birk S, Kruuse C, Petersen KA, et al. The headache-inducing effect of cilostazol in human volunteers. Cephalalgia. 2006 ; 26: 1304-1309
76. Dinn RB, Wall M. Tadalafil associated with typical migraine aura without headache. Cephalalgia. 2006 ; 26: 1344-1346
77. Jansen-Olesen I, Gulbenkian S, Engel U, et al. Peptidergic and non-peptidergic innervation and vasomotor responses of human lenticulostriate and posterior cerebral arteries. Peptides. 2004 ; 25: 2105-2114
78. Baeres FM, Moller M. Origin of PACAP-immunoreactive nerve fibers innervating the subarachnoidal blood vessels of the rat brain. J Cereb Blood Flow Metab. 2004 ; 24: 628-635
79. Gulbenkian S, Uddman R, Edvinsson L. Neuronal messengers in the human cerebral circulation. Peptides. 2001 ; 22: 995-1007
80. Hosoya M, Onda H, Ogi K, et al. Molecular cloning and functional expression of rat cDNAs encoding the receptor for pituitary adenylate cyclase activating polypeptide (PACAP). Biochem Biophys Res Commun. 1993 ; 194: 133-143
81. Lutz EM, Sheward WJ, West KM, et al. The VIP2 receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett. 1993 ; 334: 3-8
82. Harmar AJ, Arimura A, Gozes I, et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev. 1998 ; 50: 265-270
83. Hansen JM, Sitarz J, Birk S, et al. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia. 2006 ; 26: 992-1003
84. Rahmann A, Wienecke T, Hansen JM, et al. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia. 2008 ; 28: 226-236
85. Hansen J, Rahmann A, Olesen J, et al. Vasoactive intestinal polypeptide is unlikely to be a target for headache and migraine treatment. Innovative drug development for headache disorders. Ramadan N Olesen J, ed. Oxford: Oxford University Press ; 2008.
86. Schytz HW, Birk S, Wienecke T, et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009 ; 132: 16-25
87. Amin FM, Asghar MS, Guo S, et al. Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia. 2012 ; 32: 140-149
88. Schytz HW, Olesen J, Ashina M. The PACAP receptor: A novel target for migraine treatment. Neurotherapeutics. 2010 ; 7: 191-196
89. Tuka B, Helyes Z, Markovics A, et al. Peripheral and central alterations of pituitary adenylate cyclase activating polypeptide-like immunoreactivity in the rat in response to activation of the trigeminovascular system. Peptides. 2012 ; 33: 307-316
90. Baun M, Pedersen MH, Olesen J, et al. Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38. Cephalalgia. 2012 ; 32: 337-345
91. Theoharides TC, Donelan J, Kandere-Grzybowska K, et al. The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev. 2005 ; 49: 65-76
92. Wienecke T, Olesen J, Oturai PS, et al. Prostaglandin E2 (PGE2) induces headache in healthy subjects. Cephalalgia. 2009 ; 29: 509-519
93. Wienecke T, Olesen J, Ashina M. Prostaglandin I(2) (epoprostenol) triggers migraine-like attacks in migraineurs. Cephalalgia. 2010 ; 30: 179-190
94. Wienecke T, Olesen J, Ashina M. Discrepancy between strong cephalic arterial dilatation and mild headache caused by prostaglandin D (PGD). Cephalalgia. 2011 ; 31: 65-76
95. Wienecke T, Olesen J, Oturai PS, et al. Prostacyclin (epoprostenol) induces headache in healthy subjects. Pain. 2008 ; 139: 106-116
96. Antonova M, Wienecke T, Olesen J, et al. Prostaglandin E2 induces immediate migraine-like attack in migraine patients without aura. Cephalalgia. 2012 ; 32: 822-833
97. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004 ; 103: 147-166
98. Antonova M, Wienecke T, Olesen J, et al. Pro-inflammatory and vasoconstricting prostanoid PGF2alpha causes no headache in man. Cephalalgia. 2011 ; 31: 1532-1541
99. Antonova M, Wienecke T, Maubach K, et al. The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache. J Headache Pain. 2011 ; 12: 551-559
100. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol. 1981 ; 9: 344-352
101. Leão AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol. 1944 ; 7: 359-390
102. Zhang X, Levy D, Noseda R, et al. Activation of meningeal nociceptors by cortical spreading depression: Implications for migraine with aura. J Neurosci. 2010 ; 30: 8807-8814
103. Zhang X, Levy D, Kainz V, et al. Activation of central trigeminovascular neurons by cortical spreading depression. Ann Neurol. 2011 ; 69: 855-865
104. Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med. 2002 ; 8: 136-142
105. Afridi S, Kaube H, Goadsby PJ. Occipital activation in glyceryl trinitrate induced migraine with visual aura. J Neurol Neurosurg Psychiatry. 2005 ; 76: 1158-1160
106. Christiansen I, Thomsen LL, Daugaard D, et al. Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia. 1999 ; 19: 660-667
107. Cao Y, Welch KM, Aurora S, et al. Functional MRI-BOLD of visually triggered headache in patients with migraine. Arch Neurol. 1999 ; 56: 548-554
108. Hadjikhani N, Sanchez Del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA. 2001 ; 98: 4687-4692
109. Dreier JP, Kleeberg J, Petzold G, et al. Endothelin-1 potently induces Leao's cortical spreading depression in vivo in the rat: A model for an endothelial trigger of migrainous aura?. Brain. 2002 ; 125: 102-112
110. Nozari A, Dilekoz E, Sukhotinsky I, et al. Microemboli may link spreading depression, migraine aura, and patent foramen ovale. Ann Neurol. 2010 ; 67: 221-229
111. De Fusco M, Marconi R, Silvestri L, et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet. 2003 ; 33: 192-196
112. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996 ; 87: 543-552
113. Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet. 2005 ; 366: 371-377
114. van den Maagdenberg AM, Pietrobon D, Pizzorusso T, et al. A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron. 2004 ; 41: 701-710
115. Leo L, Gherardini L, Barone V, et al. Increased susceptibility to cortical spreading depression in the mouse model of familial hemiplegic migraine type 2. PLoS Genet. 2011 ; 7: e1002129 - e1002129
116. van de Ven RC, Kaja S, Plomp JJ, et al. Genetic models of migraine. Arch Neurol. 2007 ; 64: 643-646
117. Hansen J, Thomsen LL, Olesen J, et al. Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype. Neurology. 2008 ; 71: 841-847
118. Hansen JM, Thomsen LL, Olesen J, et al. Calcitonin gene-related peptide does not cause migraine attacks in patients with familial hemiplegic migraine. Headache. 2011 ; 51: 544-553
119. Hansen J, Thomsen LL, Olesen J, et al. Coexisting typical migraine in familial hemiplegic migraine. Neurology. 2010 ; 74: 594-600
120. Kelman L. Pain characteristics of the acute migraine attack. Headache. 2006 ; 46: 942-953
121. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006 ; 26: 742-746
122. Hansen JM. Familial hemiplegic migraine. Dan Med Bull. 2010 ; 57: B4183 - B4183
123. Hansen J, Thomsen LL, Marconi R, et al. Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine. Cephalalgia. 2008 ; 28: 367-375
124. Hansen J, Thomsen LL, Olesen J, et al. Familial hemiplegic migraine type 1 shows no hypersensitivity to nitric oxide. Cephalalgia. 2008 ; 28: 496-505
125. Lassen LH, Heinig JH, Oestergaard S, et al. Histamine inhalation is a specific but insensitive laboratory test for migraine. Cephalalgia. 1996 ; 16: 550-553
126. Kruuse C, Jacobsen TB, Lassen LH, et al. Dipyridamole dilates large cerebral arteries concomitant to headache induction in healthy subjects. J Cereb Blood Flow Metab. 2000 ; 20: 1372-1379
127. Birk S, Sitarz JT, Petersen KA, et al. The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept. 2007 ; 140: 185-191
128. Olesen J, Tfelt-Hansen P, Ashina M. Finding new drug targets for the treatment of migraine attacks. Cephalalgia. 2009 ; 29: 909-920